Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

suicide prevention drug

- PMLiVE

BeiGene’s Tevimbra combination granted FDA approval to treat gastric cancer

Approximately 27,000 cases of the disease were diagnosed in the US in 2024

- PMLiVE

Pfizer’s Braftovi regimen receives FDA accelerated approval to treat colorectal cancer

The disease is the third most common type of cancer globally

- PMLiVE

FDA approves Organon’s Vtama cream to treat atopic dermatitis in adults and children

More than 26 million people in the US are affected by the inflammatory skin disease

- PMLiVE

Sanofi’s BTK inhibitor tolebrutinib granted FDA breakthrough designation for MS

The neurological disorder affects approximately 2.9 million people globally

- PMLiVE

AstraZeneca’s Imfinzi granted FDA approval in limited-stage small cell lung cancer

Small cell lung cancer accounts for approximately 15% of all lung cancer diagnoses

- PMLiVE

Sanofi receives FDA fast track designation for COVID-19/flu combination vaccines

The combined vaccine approach could simplify immunisation practices and lead to higher uptake

- PMLiVE

FDA approves Shorla Oncology’s Imkeldi to treat leukaemia and other cancers

The solution is an advanced liquid formulation of the tyrosine kinase inhibitor imatinib mesylate

- PMLiVE

FDA approves BridgeBio Pharma’s Attruby to treat rare heart disease ATTR-CM

Transthyretin amyloid cardiomyopathy affects up to 500,000 people worldwide

- PMLiVE

UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults

The inflammatory skin disease affects approximately one in every 100 people in the US

- PMLiVE

Novavax announces FDA clinical hold lift on phase 3 COVID-19/flu vaccine study

The serious adverse event reported was found to be unrelated to the vaccine

- PMLiVE

FDA approves Autolus Therapeutics’ Aucatzyl to treat acute lymphoblastic leukaemia

Approximately 8,400 adults are diagnosed with the aggressive blood cancer every year in the US and EU

- PMLiVE

FDA approves Journey Medical’s Emrosi to treat inflammatory lesions of rosacea

The long-term skin condition affects more than 16 million people in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links